Chelsea Therapeutics International 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 2010
CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
The 2010 annual meeting of stockholders for Chelsea Therapeutics International, Ltd. was held on May 26, 2010.
At the meeting, our stockholders elected seven members to our board of directors for a term expiring at the annual meeting of stockholders in 2011, as follows:
At the meeting, our stockholders also approved the amendment to our Certificate of Incorporation to increase the number of authorized shares of capital stock from 65,000,000 shares to 105,000,000 shares and to increase the number of authorized shares of common stock from 60,000,000 shares to 100,000,000 shares. The vote for such approval was 29,432,643 shares for, 2,939,328 shares against (including abstentions) and no broker non-votes.
At the meeting, our stockholders also approved the amendment to our 2004 Stock Plan, as amended to increase the number of shares of common stock reserved for issuance thereunder from 5,000,000 shares to 6,200,000 shares. The vote for such approval was 17,175,520 shares for, 5,587,099 shares against (including abstentions) and 9,609,352 broker non-votes.
At the meeting, our stockholders also ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2010. The vote for such ratification was 32,319,311 shares for, 52,660 shares against (including abstentions) and no broker non-votes.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.